All In Biotech

Drug Trial Radar · NCT05322577

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

72

Actual

Start

May 17, 2022

Primary completion

Nov 21, 2025

Study completion Nov 21, 2025

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Apr 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with S-1 and oxaliplatin (SOX) and nivolumab as assessed by objective response.

Conditions

  • Gastric Cancer
  • Gastroesophageal Junction Cancer

Interventions

  • BemarituzumabDrug

    Intravenous (IV) infusion

  • CAPOXDrug

    CAPOX administered as a combination of oxaliplatin as an IV infusion and capecitabine orally as tablets.

  • SOXDrug

    SOX administered as a combination of oxaliplatin as an IV infusion and S-1 orally.

  • NivolumabDrug

    IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT)Time frame: Day 1 up to Day 21
  2. Part 1: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)Time frame: Day 1 to end of treatment (up to approximately 1 year)
  3. Part 2: Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)Time frame: Up to 30 Months

Locations

42 sites in 5 countries. Site status is shown where the registry gives one.

  • Northport Veterans Affairs Medical Center

    Northport, New York

  • Fujita Health University Hospital

    Toyoake-shi, Aichi-ken, Japan

  • Hirosaki University Hospital

    Hirosaki-shi, Aomori, Japan

  • Chiba University Hospital

    Chiba, Chiba, Japan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, Ehime, Japan

  • Fukui Prefectural Hospital

    Fukui-shi, Fukui, Japan

  • Kyushu University Hospital

    Fukuoka, Fukuoka, Japan

  • Fukushima Medical University Hospital

    Fukushima, Fukushima, Japan

  • Gifu University Hospital

    Gifu, Gifu, Japan

  • Ogaki Municipal Hospital

    Ogaki-shi, Gifu, Japan

  • Gunma University Hospital

    Maebashi, Gunma, Japan

  • Gunma Prefectural Cancer Center

    Ota-shi, Gunma, Japan

  • Hiroshima City Hiroshima Citizens Hospital

    Hiroshima, Hiroshima, Japan

  • Hiroshima University Hospital

    Hiroshima, Hiroshima, Japan

  • Ibaraki Prefectural Central Hospital

    Kasama-shi, Ibaraki, Japan

  • Ishikawa Prefectural Central Hospital

    Kanazawa, Ishikawa-ken, Japan

  • Kagawa University Hospital

    Kita-gun, Kagawa-ken, Japan

  • St Marianna University Hospital

    Kawasaki-shi, Kanagawa, Japan

  • Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan

  • Kochi Health Sciences Center

    Kochi, Kochi, Japan

  • Kyoto University Hospital

    Kyoto, Kyoto, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Okayama University Hospital

    Okayama, Okayama-ken, Japan

  • Osaka General Medical Center

    Osaka, Osaka, Japan

  • Osaka Medical and Pharmaceutical University Hospital

    Takatsuki-shi, Osaka, Japan

  • Shizuoka General Hospital

    Shizuoka, Shizuoka, Japan

  • Shizuoka Cancer Center

    Sunto-gun, Shizuoka, Japan

  • Dokkyo Medical University Hospital

    Shimotsuga-gun, Tochigi, Japan

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan

  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research

    Koto-ku, Tokyo, Japan

  • IMSUT Hospital, The Institute of Medical Science The University of Tokyo

    Minato-ku, Tokyo, Japan

  • Toyama University Hospital

    Toyama, Toyama, Japan

  • National University Hospital

    Singapore, Singapore

  • National Cancer Center

    Goyang-si Gyeonggi-do, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.